SCHEMBL1574480

SCHEMBL1574480

CCN(c1ccccc1)C1CN(C(=O)Nc2cccc(C)c2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.55
FAAH O00519 4/20 0.54
ALDH1A1 P00352 3/20 0.53
RAB9A P51151 2/20 0.52
THRB P10828 1/20 0.49
PKM P14618 1/20 0.49
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NLRP3 Q96P20 1/20 0.46
MAPT P10636 1/20 0.45
CCR5 P51681 1/20 0.45
UBE2M P61081 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
HPGD P15428 1/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574882 0.91 GRIN2B (0.53) GRIN2BFAAHALDH1A1RAB9ATHRB
SCHEMBL1574645 0.91 NPC1 (0.47) GRIN2BFAAHALDH1A1RAB9ATHRB
SCHEMBL1575133 0.89 HPGD (0.52) GRIN2BFAAHALDH1A1RAB9AMEN1
SCHEMBL1575369 0.88 GRIN2B (0.56) GRIN2BFAAHALDH1A1RAB9AMEN1
SCHEMBL1575347 0.88 NPC1 (0.53) FAAHALDH1A1SMN1; SMN2MAPTUBE2M
SCHEMBL1575107 0.87 GRIN2B (0.53) GRIN2BFAAHALDH1A1RAB9AGAA
SCHEMBL1574979 0.86 NPC1 (0.55) FAAHRAB9APKMMEN1GAA
SCHEMBL1574905 0.86 MAPT (0.54) ALDH1A1MEN1GAAKMT2ASMN1; SMN2
SCHEMBL1575188 0.86 GRIN2B (0.60) GRIN2BFAAHALDH1A1RAB9AMEN1
SCHEMBL1575357 0.86 S1PR2 (0.52) GRIN2BFAAHALDH1A1PKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB GRIN2B 3001/4885FAAH 3484/4885ALDH1A1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.